China Pharma prices $5 million registered direct offering at $2.00 per share
China Pharma Holdings agreed on July 22, 2026 to sell 2,500,000 shares of common stock at $2.00 per share, for gross proceeds of $5 million before fees and expenses, with closing expected around July 23, 2026. The company said it intends to use the net proceeds for working capital and general corporate purposes, but the sale adds new shares and includes investor participation rights and restrictions on future financings that shareholders should weigh.
Key points
- Offering: 2,500,000 shares at $2.00 per share, for gross proceeds of $5 million
- Placement agent FT Global Capital, Inc. receives a cash fee of 7.0% of aggregate proceeds
- Investor may participate in up to 40% of subsequent financings for three months after closing
- Company agreed not to enter new subsequent placements or Variable Rate Transactions until the 91st day after closing
The filing
Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 22, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.